Hyperphosphorylated tau, which is the major protein of the neurofibrillary tangles in Alzheimer's disease brain, is most probably the result of an imbalance of tau kinase and phosphatase activities in the affected neurons. By using metabolically competent rat brain slices as a model, we found that selective inhibition of protein phosphatase 2A by okadaic acid induced an Alzheimerlike hyperphosphorylation and accumulation of tau. The hyperphosphorylated tau had a reduced ability to bind to microtubules and to promote microtubule assembly in vitro. Immunocytochemical staining revealed hyperphosphorylated tau accumulation in pyramidal neurons in cornu ammonis and in neocortical neurons. The topography of these changes recalls the distribution of neurofibrillary tangles in Alzheimer's disease brain. Selective inhibition of protein phosphatase 2B with cyclosporin A did not have any significant effect on tau phosphorylation, accumulation, or function. These studies suggest that protein phosphatase 2A participates in regulation of tau phosphorylation, processing, and function in vivo. A down-regulation of protein phosphatase 2A activity can lead to Alzheimer-like abnormal hyperphosphorylation of tau.
Hyperphosphorylated tau, which is the major protein of the neurofibrillary tangles in Alzheimer's disease brain, is most probably the result of an imbalance of tau kinase and phosphatase activities in the affected neurons. By using metabolically competent rat brain slices as a model, we found that selective inhibition of protein phosphatase 2A by okadaic acid induced an Alzheimerlike hyperphosphorylation and accumulation of tau. The hyperphosphorylated tau had a reduced ability to bind to microtubules and to promote microtubule assembly in vitro. Immunocytochemical staining revealed hyperphosphorylated tau accumulation in pyramidal neurons in cornu ammonis and in neocortical neurons. The topography of these changes recalls the distribution of neurofibrillary tangles in Alzheimer's disease brain. Selective inhibition of protein phosphatase 2B with cyclosporin A did not have any significant effect on tau phosphorylation, accumulation, or function. These studies suggest that protein phosphatase 2A participates in regulation of tau phosphorylation, processing, and function in vivo. A down-regulation of protein phosphatase 2A activity can lead to Alzheimer-like abnormal hyperphosphorylation of tau.
Alzheimer's disease (AD) 1 is the most common cause of dementia in the elderly population. Although the pathogenesis of the disease is not yet understood, AD is characterized by the presence of two histopathological hallmark brain lesions, extracellular deposits of ␤-amyloid in neuritic plaques and intracellular neurofibrillary tangles. The latter is composed of bundles of paired helical filaments (PHF), the major protein subunit of which is the microtubule-associated protein (MAP) tau (1) (2) (3) (4) . Tau in PHF is different from that in normal neurons. It is abnormally hyperphosphorylated, aggregated into filaments, and does not bind to microtubules or stimulate microtubule assembly (for review see Ref. 5) . In addition to PHF, the abnormally hyperphosphorylated tau is also observed in pretangle neurons as amorphous aggregates (6) , which can be isolated from the 27,000 to 200,000 ϫ g fraction of AD brain homogenate (7) . This pool of abnormal tau, which is soluble in biological buffer conditions, disrupts microtubules and inhibits their assembly in vitro (8 -10) . Evidence from several studies has indicated that the hyperphosphorylation of tau is responsible for its loss of biological activity and its resistance to proteolytic degradation, and probably plays a key role in neurofibrillary degeneration in AD (8, (11) (12) (13) .
A fundamental question for understanding the mechanism of neurofibrillary degeneration of AD is why and how tau becomes abnormally hyperphosphorylated. The phosphorylation state of a phosphoprotein is the consequence of relative activities of the protein kinase(s) and phosphatase(s) toward it. Among several different protein kinases that have been implicated in the phosphorylation of tau are glycogen synthase kinase-3 (14) , neuronal Cdc-like protein kinases (Cdk5) (15) , mitogen-activated protein kinase (16) , Ca 2ϩ /calmodulin-dependent protein kinase II (17) , casein kinase I (18) , and cAMP-dependent protein kinase (19) . Less is known about the protein phosphatases participating in the regulation of tau phosphorylation.
To date, all the 21 phosphorylation sites that have been identified in AD hyperphosphorylated tau are either on serine or threonine residues. Thus, phosphoseryl/phosphothreonyl protein phosphatases (PP) are expected to be involved in the regulation of the phosphorylation of tau in AD brain. PP are generally classified into four types (20) , namely PP1, PP2A, PP2B, and PP2C. They are all expressed in neurons of human brain (21) . By using the abnormally hyperphosphorylated tau isolated from AD brain as a substrate, we have previously found that PP2A, PP2B, and, to a less extent, PP1 but not PP2C can efficiently dephosphorylate tau in vitro (12, (22) (23) (24) . Similar findings have also been reported by using 32 P-labeled tau with various protein kinases as a substrate in vitro (25) (26) (27) or using in vivo phosphorylated tau as a substrate (27) (28) (29) (30) . However, to date it is not known which of these three phosphatases regulates tau phosphorylation in vivo and by what mechanism tau is abnormally hyperphosphorylated in AD brain. In part, this is due to the lack of a model system for AD neurofibrillary lesions. Attempts to study the regulation of tau phosphorylation by protein phosphatases have been carried out in cultured cells (29, 31) , but this regulation in cultured cells is most likely different from that in mature mammalian brain. This is because all commonly used neuronal cell lines only express fetal type tau that is highly phosphorylated and composed of only the shortest isoform. Tau in normal mature brain is less phosphorylated and composed of six isoforms due to alternative mRNA splicing of a single gene (28) . Furthermore, the protein phosphatase profile in cultured cell lines may also be different from that in brain. For instance, PP2B is not expressed in SY5Y cells (31) , whereas it is the major protein phosphatase in mammalian brain (20) . In brains of transgenic mice lacking the catalytic subunit A␣ of PP2B, hyperphosphorylation of tau was restricted in the mossy fibers of the hippocampus (32) . Similar attempt to investigate PP2A has been unsuccessful since the selective knockout of PP2A expression is fatal (33) . Alternatively, selective PP inhibitors have been employed to be infused into animal brain or to incubate brain tissue (34, 35) . However, no convincing conclusion has been drawn due to lack of the data of the actual inhibition and/or the functional consequence.
In the present study, we have used metabolically competent rat brain slices as a model system to investigate the regulation of tau phosphorylation by protein phosphatases. The use of brain slices is a well established technique widely employed in electrophysiological and pharmacological studies (36 -38) . The brain slices have been demonstrated to be metabolically competent in oxygenated artificial cerebrospinal fluid for up to 5-8 h (36, 38) . We found that the selective inhibition of PP2A by treatment of the slices with okadaic acid induced both accumulation and phosphorylation of tau at several abnormal hyperphosphorylation sites as seen in AD brains. This hyperphosphorylation of tau occurred predominantly in pyramidal neurons in the hippocampus and neocortex. Selective inhibition of PP2B did not cause similar consequences. The phosphorylation of tau induced by PP2A inhibition in the brain slices significantly reduced its ability to bind to microtubules and to stimulate microtubule assembly.
EXPERIMENTAL PROCEDURES
Materials-Phosphorylase kinase was purified from the skeletal muscle of New Zealand White rabbits by the method of Cohen (39) . MAP-free tubulin was purified from either 1-month-old rat brains or a fresh bovine brain by two temperature-dependent cycles of microtubule polymerization-depolymerization (40), followed by phosphocellulose column chromatography (41) . Taxol-stabilized microtubules were prepared by incubating purified tubulin from bovine brain with 20 M taxol at 37°C for 30 min. Inhibitor-1 was isolated from the skeletal muscle of New Zealand White rabbits and phosphorylated by the catalytic subunit of cAMP-dependent protein kinase (Sigma) according to the method of Cohen et al. (42) . Antibodies to tau are listed in Table I . Monoclonal antibody 3G5 to MAP1b (1:500) was a gift from Dr. Lester Binder of Northwestern University, Chicago. Monoclonal antibody SMI52 to MAP2 (1:1000) was purchased from Sternberger Monoclonals, Inc., Baltimore. Alkaline phosphatase-conjugated anti-mouse and antirabbit IgG and 125 I-labeled anti-mouse and anti-rabbit whole antibody were from Sigma and Amersham Pharmacia Biotech, respectively. Phosphorylase b, cycloheximide, and actinomycin D were from Sigma. PP inhibitors ammonium salt of okadaic acid, deltamethrin, and calmidazolium chloride were bought from Calbiochem, and cyclosporin A was from Alexis Co. (San Diego, CA).
Preparation of Rat Brain Slices and Treatment with Protein
Phosphatase Inhibitors-CD rats (cesarean derived from a Wistar rat in Charles River Breeding Laboratories), male, 2-3 months old, were injected intraperitoneally with 75 mg/kg nembutal. The animals were decapitated when deeply anesthetized. The brains were immediately removed and cooled down in ice-cold (4°C) oxygenated artificial cerebrospinal fluid (CSF) consisting of 126 mM NaCl, 3.5 mM KCl, 1.2 mM NaH 2 PO 4 , 1.3 mM MgCl 2 , 2.0 mM CaCl 2 , 11 mM D(ϩ)-glucose, 25 mM NaHCO 3 , pH 7.4, for 7-8 min. The brain was then divided sagittally and 400-m-thick coronal slices were made with a Camden Vibraslicer (WP, Inc., Sarasota, FL). The slices were transferred into a chamber containing the oxygenated artificial CSF and incubated at room temperature for 1 h, followed by incubation at 33°C for 1-3 h. Various PP inhibitors were included in the artificial CSF during the incubation at 33°C. Typically 8 slices were prepared from one brain within 10 min. Half of them were treated with PP inhibitors and the other half with artificial CSF alone as controls. The oxygenation of the artificial CSF was carried out by bubbling the solution with a mixture of 95% O 2 and 5% CO 2 during the entire procedure.
At the end of incubation, the brain slices were either homogenized at 4°C for biochemical analyses or fixed for immunocytochemical studies (see below). For biochemical analyses, the brain slices were rinsed briefly with the homogenizing buffer containing 50 mM Tris-HCl, pH 7.0, 10 mM ␤-mercaptoethanol, 1.0 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 2.0 mM benzamidine, and 2.0 g/ml each of aprotinin, leupeptin, and pepstatin A. Then they were homogenized in the same buffer at a ratio of 9.0 ml of buffer/1.0-g tissue slices. The homogenates were divided into two parts. One was centrifuged at 16,000 ϫ g for 10 min, and the resulting supernatant was used for PP activity assays. Into the other half the same volume of phosphate inhibitor mixture (20 mM ␤-glycerophosphate, 2.0 mM Na 3 VO 4 and 100 mM NaF, pH 7.0) was added immediately, and the homogenates were stored at Ϫ80°C for Western blotting.
Preparation of Chopped Rat Brain Tissue and Extraction of TauRat brains obtained as described above were chopped into cubes (400 m 3 ) using a McIIwain Tissue Chopper (Brinkmann Instruments). The chopped tissue (ϳ1 g) was immediately incubated in oxygenated artificial CSF (20 ml) including 1.0 M okadaic acid or 1.0 M cyclosporin A at 33°C for 2 h. Control samples were subjected to the same procedure except that the inhibitor was omitted. After incubation, the tissue was harvested by centrifugation at low speed for 2 min and the tau was extracted from the tissue by perchloric acid extraction (8) . Briefly, the tissue was homogenized in 4ϫ volumes of 2% perchloric acid, followed by centrifugation at 100,000 ϫ g at 4°C for 30 min. Into the resulting supernatant, 10% perchloric acid was slowly added drop by drop during stirring to bring the perchloric acid concentration in the sample to 2.5%. The sample was centrifuged again at 100,000 ϫ g for 30 min, and the resulting supernatant was concentrated using an Ultrafree-15 concentrator (Millipore, Bedford, MA). After dialysis against 5.0 mM Mes, pH 6.7, containing 0.05 mM EGTA overnight, the concentrated tau extracts were lyophilized and stored at Ϫ80°C until used.
Assays of Lactate Dehydrogenase (LDH), Protein Phosphatases, and Protein Concentration-The LDH released into artificial CSF from rat brain slices during incubation was determined colorimetrically using Cytotox 96® Assay Kit (Promega, Madison, WI) according to the manufacturer's protocol. The assay was carried out on 96-well microplates, and the results were read by a kinetic microplate reader (Molecular Devices) at a wavelength of 490 nm. The activities of PP1 and PP2A in the extracts of brain slices were assayed using [ 32 P]phosphorylase a as a substrate as described by us previously (24) . A PP1-specific inhibitor, Inhibitor-1 (43) , was included in the assays for PP2A activity. PP1 activity was calculated by subtracting the PP2A activity from the total phosphorylase phosphatase activity (PP1 ϩ PP2A) assayed in the absence of Inhibitor-1. PP2B activity was measured using [ 32 P]phosphorylase kinase as a substrate according to the procedure described previously (44) except that 1.0 M calyculin A was added into the reaction mixture to inhibit completely PP1 and PP2A. Protein concentrations of all samples were quantitated by the method of Bradford (45) using the Protein Assay Reagent from Bio-Rad and bovine serum albumin as a standard.
Western Blot Analyses-The phosphorylation of tau in the above samples was analyzed by Western blots using 10% SDS-polyacrylamide gel electrophoresis (PAGE) as described originally by Laemmli (46) . The protein bands were transferred on Immobilon-P membrane (Millipore, Bedford, MA) and probed with several tau antibodies as described previously (3). As summarized in Table I , three phosphorylation-independent antibodies (92e, 111e, and 134d) were used to detect total tau. Six phosphorylation-dependent antibodies were employed to monitor the phosphorylation of tau at the specific sites they recognized, since they stain only either the phosphorylated (12E8, M4, PHF-1, R145) or unphosphorylated form (Tau-1, 102c) of tau at their specific sites. Some blots (Figs. 3 and 8) were developed with alkaline phosphatase-conjugated secondary antibodies, and 5-bromo-4-chloro-3-indoyl phosphate p-toluidine salt and p-nitro blue tetrazolium chloride as substrates. The others were developed with 125 I-radiolabeled secondary antibodies, and the radioimmunoreactivity was visualized and quantitated using a PhosphorImager (Fujifilm BAS-1500) and TINA 2.0 software (raytest Isotopenmeßgerä te GmbH). For MAP1b and MAP2 analyses, 5% SDS-PAGE was used.
Immunocytochemistry-Some of the rat brain slices after incubation at 33°C were fixed in periodate/lysine/paraformaldehyde solution (52) for 3-5 h and embedded in paraffin. Serial sections (6 m thick) were cut from the paraffin-embedded tissue slices and immunostained with antibodies Tau-1, 12E8, and R145 as described previously (3) .
Microtubule Binding Assay and in Vitro Microtubule Assembly-The ability of tau to bind to microtubules was assessed by incubating tau with taxol-stabilized microtubules and then quantitating the bound and unbound tau. This binding assay was carried out as described previously (53) except that antibody 134d instead of 92e was used to detect tau. The activity of tau to stimulate in vitro microtubule assembly was determined as described by Alonso et al. (8) . Briefly, MAP-free tubulin (2.0 mg/ml) was incubated with tau (0.18 mg/ml) and GTP (1.0 mM) in an assembly buffer at 37°C, and the turbidity of the solution was continuously monitored at 350 nm by a thermostatically controlled Cary 1 recording spectrophotometer.
RESULTS

The Selective Inhibition of PP2A and the Viability of Rat
Brain Slices-Okadaic acid has been widely used as a selective protein phosphatase inhibitor in vitro as well as in cultured cells and animals. It inhibits PP2A strongly, PP1 moderately, and PP2B weakly but does not inhibit PP2C (54) . Although only nanomolar level of okadaic acid is needed for the inhibition of isolated PP2A and lower micromolar level for PP1 (54) , the inhibition of the enzyme activities in tissue slices is not known. Therefore, we used various concentrations of okadaic acid to treat the rat brain slices to achieve a selective inhibition of protein phosphatases. We found that treatment of brain slices with 0.1 M okadaic acid achieved a 50% inhibition of PP2A ( Fig. 1 ). Approximately 70% of PP2A activity was inhibited by 1.0 M okadaic acid. When the concentration of okadaic acid was increased to 5.0 M, no more PP2A inhibition was achieved. This was probably due to a saturated permeability of okadaic acid under 1.0 M into the cells of the tissue, because PP2A activity was almost completely inhibited when the rat brain homogenate was treated with 1.0 M okadaic acid (data not shown). The inhibition of PP2A activity in brain slices was obtained within 1.5 h and kept constant during 3 h incubation. However, no apparent inhibition of PP1 or PP2B was observed at any concentration of okadaic acid used. Similarly, 1.0 -10 M cyclosporin A, a well known PP2B inhibitor, induced a selective PP2B inhibition to approximately 70%. Inhibition of both PP2A and PP2B activities was achieved by a combination of okadaic acid and cyclosporin A.
Rat brain slices prepared as described above are known to be metabolically competent and able to display active membrane potential following stimulus for up to 5-8 h (36 -38). To determine the viability of the tissue slices during the treatment with okadaic acid, we measured the LDH released from the tissue slices into the incubation solution, i.e. artificial CSF. As shown in Fig. 2 , approximately 45% of LDH was found to be released from tissue slices incubated at 33°C for 3 h without continuous oxygenation. In contrast, only ϳ7% of LDH was released when the tissue was incubated in oxygenated artificial CSF. Including 1-5 M okadaic acid in the oxygenated artificial CSF only slightly increased the LDH release. No increased LDH release was observed at all when 1-10 M cyclosporin A was used. These data suggested that during 3 h incubation with these compounds, no significant increase of cell death took place in the rat brain slices.
Alzheimer-like Hyperphosphorylation and Accumulation of Tau Induced by Selective Inhibition of PP2A in Rat Brain
Slices-In vitro studies have suggested that PP2A and PP2B are the best candidate phosphatases involved in the regulation of the phosphorylation of tau (12, (22) (23) (24) (25) (26) (27) (28) (29) (30) . Hence, we examined the phosphorylation of tau in these brain tissue slices when either PP2A or PP2B was selectively inhibited. This was carried out by Western blots using several well characterized phosphorylation-dependent and site-specific tau antibodies as listed in Table I . For example, antibody 12E8 recognizes tau only when it is phosphorylated at Ser-262 and/or Ser-356 (49) . Tau in control rat brain tissue which is largely unphosphorylated at these two sites was only faintly stained by this antibody (Fig. 3) . However, okadaic acid but not cyclosporin A treatment remarkably increased the staining, suggesting that the tau was phosphorylated at Ser-262/Ser-356 after PP2A but not PP2B was inhibited. Similar conclusions were obtained by analyzing the blots developed with antibodies PHF-1 and R145 but not with M4 (Fig. 3) , indicating that the inhibition of PP2A induced the phosphorylation of tau at Ser-396/Ser-404 (PHF-1 site) and Ser-422 (R145 site) but not at Thr-231/Ser-235 (M4 site). In contrast to above-mentioned antibodies, Tau-1 and 102c recognize only the nonphosphorylated tau at Ser-198/Ser-199/Ser-202 and Ser-46, respectively. A remarkable decrease in staining of tau with Tau-1 in okadaic acid-treated but not cyclosporin A-treated samples (Fig. 3) suggested the phosphorylation of tau at Ser-198/Ser-199/Ser-202 when PP2A but not PP2B was inhibited. An increase in staining of tau with 102c after okadaic acid treatment reflected the increase of total tau level accumulated in these treated tissue slices (see below for details) as indicated by the blot developed with 92e, a phosphorylation-independent antibody. In order to confirm the result obtained from cyclosporin A treatment that inhibition of PP2B did not induce tau phosphorylation at any of the sites we examined, we employed for these slices two other cell membrane-permeable PP2B inhibitors, deltamethrin (1.0 -10 M) and calmidazonium (10 M). Again no significant phosphorylation of tau in the tissue slices was induced by these two compounds (data not shown).
Alzheimer-like hyperphosphorylation of tau not only changes its affinity to the above phosphorylation-dependent tau antibodies but also increases its apparent molecular weight on SDS-PAGE (3, 16) . A similar mobility shift of tau in okadaic acid-treated slices was also observed on immunoblots developed with 92e, 102c, and 12E8 (Fig. 3) . No such mobility shift was seen in samples in which PP2B was inhibited. We unexpectedly found that in addition to hyperphosphorylation of tau, the inhibition of PP2A in the tissue slices by okadaic acid also induced an increase in tau protein level. This is clearly demonstrated on the blot developed with 92e (Fig. 3) which recognizes tau regardless of its phosphorylation state. This finding was confirmed with two other phosphorylationindependent anti-tau antibodies, R111 and R134d. As shown in Table I . The molecular mass markers (69 and 43 kDa, respectively) are shown at the left of each blot. Each pair of untreated (Ϫ) and treated (ϩ) samples was from the same rat. The differences in immunostainings among untreated samples probably represent the individual variations. Note that although the tau level increases after okadaic acid treatment as shown on 92e blot, the immunoreactivity with Tau-1 decreases due to tau phosphorylation at this epitope. The increase in tau phosphorylation in okadaic acid-treated tissue after normalized to the level of tau is also found at 12E8, PHF-1, and R145 epitope sites, and the quantitative analyses are presented in Fig. 5 . Increased tau level in okadaic acid-treated samples was detected by the phosphorylation-independent anti-tau antibodies R111e and R134d. However, the tubulin level detected using antibody DM1A was not changed after the slices were treated with okadaic acid. B, when the incubation of brain slices was carried out in the presence of the protein synthesis inhibitors cycloheximide or actinomycin D, the increase in tau level persisted in okadaic acid-treated samples. Fig . 4A , these two antibodies also detected an elevated level of tau in okadaic acid-treated tissue slices as compared with the slices incubated in the artificial CSF alone as a control. In contrast, the level of another cytoskeletal component, tubulin, was not affected by this treatment as evidenced by the immunoblot with anti-tubulin antibody DM1A (Fig. 4A) . The accumulation of tau in neurons of the brain slices after okadaic acid treatment was also confirmed by immunocytochemical staining of the thin sections cut from these slices. When the sections were stained with Tau-1 after pretreatment with alkaline phosphatase to dephosphorylate the proteins (3), we observed a significant increase in the staining of the pyramidal neurons of the hippocampus and of most neurons in neocortex in the okadaic acid-treated tissue as compared with artificial CSFtreated tissue control (data not shown).
To learn whether the tau accumulation was due to an increased expression of tau or an inhibition of its degradation by okadaic acid treatment, we incubated brain slices with okadaic acid together with cycloheximide, a commonly used protein synthesis inhibitor. In rat brain slices incubated in artificial CSF, 3.5 M cycloheximide inhibits 90% of protein synthesis as determined by counting 3 H incorporation into the proteins (55). Cycloheximide at 10 M has been shown to block completely the brain-derived neurotrophic factor-induced protein synthesis in rat hippocampal slices (56) . In the present study, we used 5.0 g/ml (equal to 17.8 M) cycloheximide to block the protein synthesis. We found that the blockage of newly synthesized protein did not prevent the increase of tau level induced by okadaic acid in the tissue slices (Fig. 4B, lanes 1-4) . To confirm this result, we employed 1.0 g/ml actinomycin D instead of cycloheximide to block new protein synthesis; actinomycin D at 0.5 g/ml has previously been shown to inhibit nearly completely protein synthesis (77) . The blockage of newly synthesized protein by 1.0 g/ml actinomycin D did not diminish the increase of tau level in okadaic acid-treated slices either (Fig.  4B, lanes 5-8) . These data suggested that the tau accumulation may result from an inhibition of tau degradation rather than an increase in tau expression after okadaic acid treatment.
The time kinetics of the phosphorylation and accumulation of tau induced by various concentrations of okadaic acid was investigated. When rat brain slices were treated with various concentrations of okadaic acid for 3 h, a concentration-dependent increase of both tau level and tau phosphorylation was observed (Fig. 5A) . When the radioimmunoreactivity of tau with each antibody was normalized against that of antibody 92e, okadaic acid at 10 nM did not have any significant effect. A moderate increase of both tau level and phosphorylation at Tau-1, 12E8, PHF-1, and R145 sites was obtained with 100 nM okadaic acid. Maximal effect was seen with 1.0 M okadaic acid except at the R145 site the phosphorylation was increased with 5.0 M okadaic acid treatment (Fig. 5A) . Although there was a concentration-dependent increase in the staining of tau with antibody 102c (Fig. 5A) , this increase was quantitatively the same as that seen with antibody 92e, reflecting the concentrationdependent increase in tau level in these samples. When the brain slices were incubated in the oxygenated artificial CSF at 33°C in control cases, tau phosphorylation at the PHF-1 site (Ser-396/Ser-404) was slightly increased at 1 h and kept constant during 3 h incubation (Fig. 5B) . Phosphorylation of tau at the 12E8 site (Ser-262/Ser-356) was slightly increased only The homogenates (10 g of protein/lane) of these slices were then analyzed by Western blots to assess the phosphorylation levels of tau at the specific sites recognized by phosphorylation-dependent and sitespecific anti-tau antibodies Tau-1, 102c, 12E8, PHF-1, and R145 as summarized in Table I . In order to quantitate the phosphorylation level of tau at the specific sites recognized by these antibodies, the blots (right panels) were scanned, and the radioimmunoreactivity was quantitated using a PhosphorImager. Since the level of tau increased after okadaic acid treatment, the radioimmunoreactivity with each antibody demonstrated in the left panels was normalized by the increase of the total tau level in each case. This was done by dividing the radioimmunoreactivity obtained with each antibody by that with 92e, a phosphorylation-independent antibody that detects total tau proteins of each lane. Therefore, the data in bar graphs represent the increase in phosphorylation level at the specific sites over the increase in total tau. The bar graphs are presented as means Ϯ S.D. of four independent experiments. after 3 h incubation. The slight increase in tau phosphorylation at above sites might be due to activation of some protein kinases as a result of tissue stress, since stress-activated protein kinases can phosphorylate tau at these sites (78) . No apparent phosphorylation of tau at R145 site (Ser-422) was observed during this 3-h control incubation. However, when 1.0 M okadaic acid was added into the artificial CSF for the incubation, a remarkable time-dependent increase in tau phosphorylation at these sites was observed (Fig. 5B) .
Immunocytochemistry of Hyperphosphorylated Tau Induced by Inhibition of PP2A-To learn the topographical distribution of the hyperphosphorylation and accumulation of tau induced after inhibition of PP2A by okadaic acid and the histocytochemical changes in the brain tissue, we immunostained the sections cut from these brain slices with several phosphorylationdependent anti-tau antibodies. A time-and concentration-dependent increase in tau staining was found in the soma of neurons and neuropil in the neocortex and hippocampus with antibodies that recognize only the phosphorylated form of tau. For example, a remarkable increase in immunostaining with antibody 12E8 was seen in both neocortical and hippocampal neurons and the neuropil in 1.0 M okadaic acid-treated sections as compared with controls (Fig. 6) . The cornu ammonis and dentate gyrus displayed a lamina-specific immunoreactivity (Fig. 6, e and f) . Similar results were seen when antibody R145 was used instead (Fig. 7) . A lamina-specific increase in the staining of both neocortex and hippocampal formation was observed. The lamina specificity seemed different when different antibodies were employed. This suggested that in any topographical location, some specific sites of tau are more susceptible to phosphorylation than other sites.
Although antibodies 12E8 and R145 only very faintly stained neurons in control sections, they decorated strongly the pyramidal cells and some granular cells in the neocortex and cornu ammonis and dentate gyrus in okadaic acid-treated sections. Some of these strongly stained neurons looked like "stage 0" pretangles in AD brain (Figs. 6c and 7f) (6) . However, in sections stained with thioflavin-S, a bright fluorescence typical for neurofibrillary tangles was absent in the okadaic acid-treated tissue (data not shown). These results suggested that the inhibition of PP2A by okadaic acid for 3 h induced a hyperphosphorylation and accumulation of tau in selected neurons in the brain slices but did not induce a formation of filaments from the hyperphosphorylated tau.
Biological Activity of the Hyperphosphorylated Tau Induced by Inhibition of PP2A with Okadaic Acid-The consequence of the okadaic acid-induced phosphorylation on the biological activity of tau was assessed by investigating its ability to bind to microtubules and to stimulate microtubule assembly in vitro. Since it was not practical to isolate tau from 400-m-thick brain slices, we used chopped rat brain tissue instead for these studies. Like brain slices (Fig. 3) , the chopped tissue also produced the hyperphosphorylation of tau at Tau-1, 12E8, and R145 sites after okadaic acid treatment (Fig. 8A) . Tau isolated by perchloric acid extraction from chopped tissue was free from high molecular weight MAPs, MAP1b and MAP2, as examined by immunoblots developed with antibody 3G5 and SMI52, respectively (Fig. 8A) . A significant decrease in binding of the okadaic acid-induced hyperphosphorylated tau to taxol-stabilized microtubules was observed (Fig. 8B) .
The effect of the okadaic acid-induced hyperphosphorylation on the biological activity of tau was also examined by assaying its ability to promote the microtubule assembly in vitro. Tau isolated from the okadaic acid-treated tissue had only approximately 60% of the microtubule assembly promoting activity of tau from the control-treated tissue (Fig. 8C) . When the micro- tubule assembly reached a plateau, i.e. after 7 min incubation at 37°C, we cooled down the assembly reaction mixture to 4°C and observed that the optical density dropped almost to base line. When the solutions were rewarmed up to 37°C, an increase in turbidity consistent with microtubule assembly reaction was observed (data not shown). These results together indicated that the hyperphosphorylation of tau induced by PP2A inhibition with okadaic acid inhibited its biological activity in promoting microtubule assembly.
In this study, we examined 11 phosphorylation sites of tau by phosphorylation-dependent and site-specific tau antibodies (see Table I ), and we did not find any significant increase in phosphorylation at any of these sites in tissue slices treated with PP2B inhibitors. However, PP2B inhibition might affect the ability of tau to bind to microtubules and to stimulate microtubule assembly by inducing phosphorylation of tau at other unexamined sites. Hence, we studied the biological activity of tau isolated from chopped rat brain tissue after incubation with 1.0 M cyclosporin A. We did not find any significant alteration of its ability to bind to microtubules or to stimulate microtubule assembly as compared with tau isolated from control-treated tissue (data not shown). These results suggested that PP2B inhibition did not induce phosphorylation of tau at any sites that affect its activity in binding to microtubules or promoting their assembly.
DISCUSSION
The biological activity of tau, which is the major microtubuleassociated protein of normal mature neurons, is known to be regulated by the degree of its phosphorylation. Hyperphosphorylation of tau depresses its activity to promote microtubule assembly and to maintain the structure of microtubules (8, 9, 57). Thus, understanding the regulation of tau phosphorylation is of great importance not only in AD, which is characterized by the accumulation of the abnormally hyperphosphorylated tau in the affected neurons, but also in normal neurobiology. In vitro studies employing purified enzymes have shown that tau can be dephosphorylated by PP2A, PP2B, and PP1 but not by PP2C (12, (22) (23) (24) . In the present studies employing metabolically active rat brain slices, we have found that the phosphorylation of tau at some of the same sites phosphorylated in AD is regulated by PP2A and that the inhibition of the activity of the phosphatase also results in an increase in the level of tau due to a decrease in its turnover. Inhibition of PP2B by cyclosporin A, deltamethrin, or calmidazonium did not result in any significant increase in tau level nor tau hyperphosphorylation at any of the sites examined. Tau isolated from cyclosporin A-treated rat brain tissue had normal activity to bind to microtubule and to promote microtubule assembly. These data taken together suggest that the phosphorylation and processing of tau in vivo are regulated mainly by PP2A and that PP2B is minimally involved in regulating the phosphorylation of tau at the sites that affect its microtubule binding and assembly activities.
The present findings are consistent with previous reports, which found the following: 1) that a pool of PP2A is associated with microtubules (58, 59, 75) ; 2) that in three different cell lines, coexpression of tau with SV40 small t, a specific endogenous PP2A inhibitor, increased tau phosphorylation and decreased microtubule stabilization (59); 3) that the inhibition of protein phosphatases by okadaic acid and calyculin A in cultured fetal rat hippocampal neurons resulted in a modification of the neuritic tree structure with loss of neuronal process and decrease in the number of synapses as seen in AD brain (60) cells induced dephosphorylation of tau at Ser-202 and Thr-205, and this dephosphorylation could be blocked by PP2A inhibitor but not by PP2B inhibitor (61, 62) ; 5) that a complete block of PP2B activity in the knockout mice induced hyperphosphorylation of tau only in the mossy fibers of CA3 region of the hippocampus, where PP2B is most dominant (32); and 6) that a 38% inhibition of PP2B induced by injection of cyclosporin A into rat brain hippocampus failed to induce hyperphosphorylation of tau (63) . Tau in both normal human brains and animal brains but not in AD brain are subjected to rapid enzymatic dephosphorylation during postmortem (64) . We have previously shown that PP2A activity is declined in AD brain as compared with controls (65, 66) . Thus, it appears that the phosphorylation of tau is regulated by PP2A in vivo, and a defect in PP2A activity may contribute to hyperphosphorylation and consequent aggregation and loss of biological function of tau in AD brain.
The regulation of the phosphorylation of tau appears quite complex. Tau has been reported to serve as a bridge between PP1 and microtubules, and a pool of PP1 copurifies with microtubules (76) . The association of PP1 with tau increases the phosphatase activity 3-4-fold in vitro. In contrast, the holoenzyme of PP2A has been shown to bind to both tau and microtubules, and this binding inhibits PP2A activity toward tau (75) . These findings suggest that PP2A may dephosphorylate tau primarily, if not extensively, when tau is dissociated from microtubules, and the dephosphorylated tau regains its ability to bind to microtubules. Thus, as observed in the present study, the inhibition of PP2A activity keeps tau dissociated from microtubules and available for continuous phosphorylation by various protein kinases in neurons.
The relative activities of tau protein kinase(s) and phosphatase(s) determine the degree of phosphorylation of the protein in the cells. When PP2A is inhibited or declined, the balance of tau phosphorylation will shift toward the hyperphosphorylation side. In addition to the direct action of PP2A on tau, the activation of tau protein kinases can also induce tau hyperphosphorylation. We (31) and others (73) have previously shown that the treatment of cultured cells by okadaic acid activated transiently the activities of several protein kinases including MAP kinase, cyclin-dependent protein kinases (Cdc2 kinase and Cdk5), and Ca 2ϩ /calmodulin-dependent protein kinase II, all of which are able to phosphorylate tau in vitro (15, 16) . Hence, the tau hyperphosphorylation we observed in okadaic acid-treated brain slices could also be the result of the activation of these kinases. However, okadaic acid does not seem to have any direct effect on protein kinases; the activation of these kinases appears to be the result of inhibition of PP2A/ PP1 (73, 74) . Activation of MAP kinase and Cdc2 kinase is unlikely involved in the hyperphosphorylation of tau observed in the present study. MAP kinase has been reported not to participate to tau phosphorylation in vivo (67) , even though it can phosphorylate several phosphorylation sites of tau in vitro (16) . The Cdc2 kinase is usually inactive in mature neurons, and one of its preferred phosphorylation sites, Thr-231 (68), was not phosphorylated in the okadaic acid-treated tissue slices as determined with antibody M4 in the present study.
PHF-tau is highly phosphorylated. To date, 21 phosphorylation sites have been identified in PHF-tau, only some of which are partially phosphorylated in normal brain (64, 69) . The abnormally hyperphosphorylated tau displays a mobility shift on SDS-PAGE (3, 16), a resistance to proteolytic degradation (12) , and a loss of its ability to bind to microtubules and to promote microtubule assembly (8, 12) , and an AD brain (lane 6) for comparison. Antibody 92e recognizes total tau regardless of its phosphorylation state, whereas Tau-1, 12E8, and R145 stain tau in a phosphorylation-dependent manner as described in Table I . The molecular mass markers are indicated at the left of the blots. Note that an increase in tau phosphorylation induced by okadaic acid treatment was confirmed by immunostaining with Tau-1, 12E8, and R145. The contamination of the isolated tau preparations with MAP1b and MAP2 was checked by Western blots using antibodies 3G5 and SMI52, respectively. None of these contaminants were observed (lanes 2-4) . Degradation of MAP1b, and especially MAP2, was observed in the postmortem human brain homogenates (lanes 5 and 6 in panels 3G5 and SMI52). Arrows indicate the origin of the separating gel. B, binding of tau isolated from the chopped rat brain tissue to microtubules. The tau preparations (0.25 g) were incubated with taxol-stabilized microtubules (5.6 g) at 37°C for 30 min, followed by centrifugation to separate bound tau from unbound tau. Both the supernatant (containing unbound tau) and the pellet (containing bound tau) were analyzed by Western blots using antibody 134d and 125 I-labeled anti-rabbit IgG. The percentage of the bound tau over total tau was calculated by quantitating these blots with a PhosphorImager. Note that the microtubule binding activity of tau was significantly decreased after phosphorylation induced by okadaic acid treatment of the tissue. C, in vitro microtubule assemblypromoting activity of tau isolated from chopped rat brain tissue. The microtubule assembly was carried out by incubating rat brain tubulin (2.0 mg/ml) with the tau preparations (0.18 mg/ml) at 37°C in cuvettes, and the change in turbidity was monitored at 350 nm. Tubulin alone was included as a background control. Note that tau isolated from okadaic acid-treated tissue displayed an impaired activity to stimulate microtubule assembly as compared with that from the control-treated tissue.
abnormal hyperphosphorylated sites found in PHF-tau (69) . The inhibition of PP2A activity by okadaic acid might have also induced phosphorylation of tau at the sites in addition to those examined. The mobility shift, the resistance to degradation, and the functional inhibition of the tau reported in AD brain were also observed in the okadaic acid-treated rat brain tissue. However, unlike AD abnormal tau, the okadaic acid-induced phosphorylated tau only displayed partial inhibition to bind to microtubules and to stimulate their assembly. Thioflavin-S staining of the okadaic acid-treated rat brain sections indicated no PHF formed from this hyperphosphorylated tau. These results suggest that the inhibition of PP2A activity for an extended period might be required and/or other factors might be involved in the formation of PHF. AD brain is characterized by containing numerous extracellular neuritic plaques and intracellular neurofibrillary tangles made from the abnormally hyperphosphorylated tau. The latter are widely distributed through out the gray matter of AD brain, especially in entorhinal cortex and CA1 sector of the hippocampus (70) . Among various neurons, pyramidal cells are most susceptible to Alzheimer neurofibrillary degeneration. The distribution of neurons containing the hyperphosphorylated tau in the okadaic acid-treated rat brain slices as examined by immunocytochemical staining with 12E8 and R145 was similar to that of neurofibrillary tangles in AD brain. This further supports our hypothesis that a down-regulation of PP2A may be involved in neurofibrillary degeneration in AD.
Okadaic acid is a well documented inhibitor of PP2A and PP1, with an IC 50 of ϳ1 nM and 0.1-0.5 M, respectively, in vitro (54) . It can also inhibit PP2B activity at a much higher concentration (IC 50 ϭ 4 -5 M). This compound has been widely used for selective inhibition of protein phosphatases. However, due to the high concentration of protein phosphatases and the complexity inside the cell, the intracellular selectivity of phosphatase inhibition cannot be speculated according to its in vitro potency to each protein phosphatase. This has made the interpretation of the data inconclusive, often unable to distinguish between the roles of PP2A and PP1. In this study, we have employed various concentrations of okadaic acid to treat the brain slices and quantitated the remaining activity of each phosphatase. Surprisingly, we found that only PP2A activity of the slices was inhibited by okadaic acid at concentrations up to 5 M, which can completely block PP1 activity in vitro (54) . This result raises concerns for a possible misleading interpretation of similar data according to in vitro inhibitory potency of okadaic acid (34) . Why a much higher concentration of okadaic acid is needed for the tissue slices than in vitro to achieve the same selective inhibition may be due to the following reasons. First, the intracellular concentration of okadaic acid may be far lower than that in the incubation medium. Actually, a recent report demonstrated that the permeability of okadaic acid across the cell membrane is much lower than generally believed (71) . Second, the concentration of cellular protein phosphatases is much higher than that employed in vitro. The higher concentration of protein phosphatases demands a higher concentration of okadaic acid to achieve the same inhibition. This has also been suggested by other investigators (38, 72) . Third, there might be other proteins in the intracellular compartment that also bind to okadaic acid, and as a consequence less free okadaic acid is available for protein phosphatase inhibition.
In summary, selective inhibition of PP2A in metabolically competent rat brain slices by okadaic acid induced an Alzheimer-like hyperphosphorylation, accumulation, and dysfunction of tau. Taken together with previous findings that PP2A is associated with microtubules (58) and is the major brain phosphatase active toward in vitro phosphorylated tau (26) , and that PP2A activity is compromised in AD brain (65, 66) , we suggest that PP2A participates in regulation of tau phosphorylation in vivo, and a defect in PP2A activity may be responsible for abnormal hyperphosphorylation of tau in AD. Further studies on why and how PP2A is down-regulated in AD brain might lead to a better understanding of the neurofibrillary degeneration in AD.
